TWiV 831: COVID-19 clinical update #89 with Dr. Daniel Griffin
About this episode
In COVID-19 clinical update #89, Dr. Griffin reviews upcoming meeting on FDA emergency use authorization for molnupiravir, 25% of US cases in children, reinfection associates with presence of antibodies, national surveillance for acute flaccid myelitis in the US, and monoclonal antibody treatment of infection in vaccinated, high-risk individuals.
Hosts: Daniel Griffin and Vincent Racaniello
Subscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Scott Hammer on TWiV 52
- Meeting for molnupiravir EUA (FDA)
- SARS-CoV-2 reinfection associates with antibodies (Clinical Inf Dis)
- AFM surveillance in US (CDC)
- Monoclonal antibody treatment in high-risk patients (J Inf Dis)
- Letters read on TWiV 831
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]
Get every episode summarized
Each time This Week in Virology publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from This Week in Virology
TWiV 1309: Maybe they're all cancer vaccines
This Week in Virology
TWiV 1308: Clinical update with Dr. Daniel Griffin
This Week in Virology
TWiV 1307: My heart breaks for flu
This Week in Virology
TWiV 1306: Clinical update with Dr. Daniel Griffin
This Week in Virology